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Background: Post-challenge hyperglycemia (PH) is well-established as one of risk factors for coronary artery
disease. However, it remains unclear whether PH affects clinical outcomes in patients with stable angina
undergoing percutaneous coronary intervention (PCI).
Methods: A total of 828 patients with stable angina undergoing PCI were retrospectively analyzed. Of these,
452 patients with previously diagnosed diabetes mellitus (DM) or fasting plasma glucose (PG) ≥126 mg/dl and
HbA1c ≥6.5% were defined as known DM. The remaining 376 patients were divided into the two groups
according to 2-h PG: PH (2-h PG ≥140 mg/dl, n=236) and normal glucose tolerance (NGT, 2-h PG <140 mg/dl,
n=140). We assessed the rate of major adverse cardiovascular events (MACE), defined as a composite of
cardiovascular death, myocardial infarction, stroke, and clinically-driven revascularization.
Results: During the median follow-up of 4.3 years, the MACE rate was significantly higher in the DM and PH groups
than the NGT group (39.3% vs. 20.7%, P <0.001; 31.4% vs. 20.7%, P=0.044, respectively). Compared with the NGT group,
the cumulative incidence of revascularization was significantly higher in the DM group (35.1% vs. 18.5%, P <0.001) and
tended to be higher in the PH group (27.1% vs. 18.5%, P=0.067). In the multivariate analysis, known DM (Hazard ratio
[HR]: 2.16, 95% confidence interval (CI): 1.49-3.27, P < 0.001), PH (HR: 1.62, 95% CI: 1.07-2.53, P = 0.023), LDL-C >100 mg/
dl (HR: 1.62, 95% CI: 1.26 to 2.10, P < 0.001), and previous stroke (HR: 1.47, 95% CI: 1.03-2.04, P = 0.034) were predictors
of MACE.
Conclusion: PH is associated with future cardiovascular events in patients with stable angina undergoing PCI.
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Diabetes mellitus (DM) is an important public health
problem. Its prevalence is variable and increases with
age; in the USA 9.6% of the population aged over 20
years suffers from known DM [1]. DECODE (Diabetes
Epidemiology: Collaborative Analysis of Diagnostic
Criteria in Europe) study reported that the prevalence
of DM and impaired glucose tolerance (IGT) in elderly
individuals is 10 - 20% and 30 - 35%, respectively [2].
In Japan, the prevalence of glucose intolerance among
the general population is 31.9%, which is increasing
with time, possibly as a consequence of rapid changes
in lifestyle by the Japanese population since the late
1980s [3,4].
Type 2 DM is associated with a 2- to 4-fold increased
risk of cardiovascular events [5]. Several clinical trials
have demonstrated that the post-challenge hypergly-
cemia (PH) is associated with adverse cardiovascular
events [2,6-9]. Furthermore, a meta-analysis showed that
hyperglycemia in the non-diabetic range was associated
with the increased risk of fatal and non-fatal cardiovas-
cular disease [10]. Macrovascular disease is a common
diabetic complication and the leading cause of death
among people with type 2 DM [11]. In particular, coron-
ary artery disease (CAD) is one of major macrovascular
complications in patients with type 2 DM.
In patients with CAD, the prevalence of DM is greater
compared to that of general population [12-14]. Moreover,
the prevalence of PH in patients undergoing angiography
exceeds 60% and is associated with the angiographically
determined extent of coronary artery disease [14]. How-
ever, the impact of PH on clinical outcomes in patients
with stable angina undergoing percutaneous coronary
intervention (PCI) has not been fully elucidated. There-
fore, the aim of the present study was to evaluate whether
newly diagnosed PH affects clinical outcomes in Japanese
patients with stable angina undergoing PCI.
Methods
Study selection, procedure, and follow-up
A total of 1227 consecutive patients with stable an-
gina underwent elective PCI with stent implantation
at Kokura Memorial Hospital between October 2007
and March 2009. Of these, 277 patients were ex-
cluded because of (1) being older than 80 years; (2)
a serum creatinine level ≥2.0 mg/dL; (3) type 1 DM;
(4) concomitant diseases such as neoplasm, hepatic
failure, or severe infection; (5) imcomplete revascu-
larization at the time of hospital discharge; (6) com-
plications associated with the procedure such as
cerebral infarction and myocardial infarction; and (7)
having acute coronary syndrome within 3-months
prior to PCI. Finally, 950 patients were enrolled in
this study. All interventions were performed usingstandard techniques. Predilatation, postdilatation, and stent
selection were left to the operator’s discretion. After the
procedure, all patients were advised to continue on aspirin
(81 to 162 mg daily) for life unless there were contraindi-
cations. Either ticlopidine (200 mg daily) or clopidogrel
(75 mg daily) was also prescribed for at least 1-month
after bare-metal stent implantation, and 1 year after drug-
eluting stent implantation. Follow-up data were retro-
spectively collected from a review of the hospital record or
by telephone contacts with the patients, the family mem-
bers, or the family physicians. This study was approved by
the ethics committee of Kokura Memorial Hospital.
Measurement and diagnosis of the glucometabolic status
The glucometabolic status of each patient before hospi-
talization was evaluated by medical questionnaire and out-
patient records. Patients were classified as having known
DM if they had a recorded history of DM or if they were
on a diet or medical treatment for DM. In addition, pa-
tients with fasting plasma glucose (FPG) level ≥126 mg/dl
and HbA1c ≥6.5% at the time of admission were also clas-
sified as having known DM. In patients without overt DM,
a 75-g oral glucose tolerance test (OGTT) was performed
at the time of discharge.
The remaining patients with FPG <126 mg/dl and
HbA1c <6.5% were divided into the 2 groups according to
2-h plasma glucose (PG) classification adopted by Ameri-
can Diabetes Association criteria [15]. Patients with 2-h
PG after the 75-g glucose load <140 mg/dl were classified
as having a normal glucose tolerance (NGT). IGT was di-
agnosed in patients with 2-h PG between 140 and 199
mg/dl. Newly detected DM was diagnosed in patients with
2-h PG ≥200 mg/dl. According to the definition in a previ-
ous study [16], PH was defined as a composite of IGT and
newly detected DM.
The value for HbA1c (%) was estimated as a National
Glycohemoglobin Standardization Program equivalent
value (%) calculated by the following formula: HbA1c
(%)=HbA1c [value] +0.4, considering the relational ex-
pression of HbA1c (Japan Diabetes Society value, %)
measured using the previous Japanese standard sub-
stance and measurement methods [17].
Definitions of other coronary risk factors
Other coronary risk factors of each patient before
hospitalization were evaluated by medical questionnaire
and outpatient records. If the patients met the following
criteria, these diseases were added to the baseline char-
acteristics: hypertension, systemic arterial pressure >140
mmHg or diastolic arterial pressure >90 mmHg or treat-
ment with anti-hypertensive agents; dyslipidemia, LDL
cholesterol (LDL-C) >140 mg/dl or HDL cholesterol <40
mg/dl or triglyceride >150 mg/dl or treatment with any
lipid lowering agents.
Figure 1 Overview of patient enrollment. DM = diabetes
mellitus; OGTT = oral glucose tolerance test; PCI = percutaneous
coronary intervention.
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The study endpoint was the cumulative incidence of
major adverse cardiovascular events (MACE), which was
a composite of cardiovascular death, stroke, myocardial
infarction (MI), clinically-driven revascularization. Car-
diovascular death was defined as death from MI, stroke
or sudden death without any obvious reasons. The diag-
nosis of acute MI (AMI) was established according to
the universal definition of MI [18]. A clinically-driven re-
vascularization was defined as treatment for recurrent
angina in the presence of signs or symptom of myocar-
dial ischemia, including target lesion revascularization
(TLR), target vessel revascularization (TVR), non-target
vessel revascularization (non-TVR), or coronary artery
bypass graft (CABG). TLR was defined as repeat revas-
cularization caused by a 50% stenosis within or within a
5-mm border proximal or distal stent. TVR was defined
as any repeat PCI of any segment within the entire
major coronary vessel that was proximal or distal to a
target lesion, and the target lesion itself. Non-TVR was
defined as any PCI of either of the major coronary arter-
ies not including the target vessel.
Statistical analysis
Data are presented as values and percentages, mean ± SD,
or median (interquartile range). Analysis of normality
of the continuous variable was performed with the
Shapiro-Wilk test. Comparisons among the three groups
(known DM, PH, and NGT) were examined using one-
way analysis of variance (ANOVA) or Kruskal-Wallis test
for continuous variables, and chi-square test or Fisher’s
exact test for categorical variables, as appropriate. In the
case of significant P values for ANOVA or Kruskal-Wallis
test, the Tukey-Kramer test or Steel-Dwass test were used
for multiple comparisons among groups, respectively.
Comparisons for post-challenge 2-h PG between PH and
NGT were made using the Mann–Whitney U test. The
cumulative incidence of the MACE was estimated
according to the Kaplan-Meier method. The log-rank
test and hazard ratio were used to evaluate the differ-
ences between the incidence curves of the three groups.
To identify independent predictors of the endpoints,
Cox proportional hazard regression analysis was used.
Univariate analysis was performed with 24 baseline
characteristics and laboratory profiles. The insulin and
OHA use were not included in univariate analysis be-
cause they were used only in patients with known DM.
The following 8 variables with P <0.05 in the univariate
analysis were tested for their multivariate predictive value:
glucometabolic status (known DM, PH, and NGT), total
cholesterol >220 mg/dl , LDL-C >100 mg/dl, previous
stroke, FPG, and HbA1c.The final model was constructed
using the 5 variables: glucometabolic status (known DM,
PH, and NGT), previous stroke, and LDL-C >100 mg/dlselected by forward stepwise method, with entry and exit
criteria test at the P=0.05 and P=0.10 levels, respectively.
A 2-sided P value less than 0.05 was considered statisti-
cally significant. Statistical analysis was performed using
JMP, version 10.0.2 (SAS Institute Inc., Cary, NC, USA)
and SPSS, version 16 (SPSS Inc., Chicago, IL, USA)Results
Study population
Of the 950 patients, the 75-g OGTT was not performed
in 452 patients with known DM and another 120 pa-
tients without a previous diagnosis of DM. A 75-g
OGTT was conducted on the remaining 378 patients
(75.9% of the eligible population). According to the re-
sults of the 75-g OGTT, 236 (100 newly diagnosed DM
and 136 IGT) and 140 patients were divided into PH
and NGT patients, respectively. During the median
follow-up period of 4.3 (interquartile range, 3.8 to 4.9)
years, a total of 828 patients (452 DM, 236 PH, and 140
NGT) were analyzed (Figure 1).Baseline characteristics of the study population and
glucometabolic status
The baseline characteristics of our study population are
shown in Table 1. The median age was 69.0 years, and
78.8% of the patients were men. Most subjects had hyper-
tension, followed by dyslipidemia. Compared with the
NGT group, the body-mass index (BMI) and the preva-
lence of hypertension, previous PCI, oral hypoglycemic
agents and insulin use were significantly higher, and the
left ventricular ejection fraction was significantly lower in
the DM group (P <0.05, respectively). Furthermore, the
prevalence of male gender, BMI, and hypertension was
Table 1 Baseline clinical characteristics of the 3 groups
DM (n=452) PH (n=236) NGT (n=140) P value
Age, years 70 (62–74)* 67 (59–72) 69 (62–74) 0.002
Male 347 (76.7) 203 (86.0)†‡ 103 (73.5) 0.004
Hypertension 380 (84.0) 185 (78.3) 104 (74.2) 0.019
Dyslipidemia 295 (65.2) 164 (69.4) 101 (72.1) 0.24
Current smoking 119 (26.3) 74 (31.3) 34 (24.2) 0.24
Previous PCI 249 (55.0)*† 104 (44.0) 66 (47.1) 0.015
Previsou CABG 33 (7.2) 9 (3.8) 10 (7.1) 0.18
Previous MI 148 (32.7) 63 (26.6) 39 (27.8) 0.2
Previous CI 55 (12.1) 27 (11.4) 11 (7.8) 0.36
Multivessel disease 128 (28.3) 59 (25.1) 29 (20.7) 0.18
BMI, kg/m2 24.3 (22.1-26.4)† 24.7 (22.9-26.6)† 23.2 (21.0-25.7) <0.001
LVEF, % 61.0 (50.0-68.0)* 64.0 (55.0-69.0) 64.0 (50.2-68.0) 0.017
eGFR, ml/min./1.73m2 64.9 (51.4-76.1) 66.2 (57.5-75.1) 65.6 (54.6-79.6) 0.17
Stent type 0.057
BMS 255 (56.4) 146 (61.8) 94 (67.1)
DES 197 (43.6) 90 (38.2) 46 (32.9)
Medication at discharge
Aspirin 452 (100.0) 236 (100.0) 140 (100.0) -
Thienopyridine 452 (100.0) 236 (100.0) 140 (100.0) -
β-blocker 136 (30.0) 78 (33.0) 41 (29.2) 0.66
ACE-I 117 (25.8) 48 (20.3) 27 (19.2) 0.12
ARB 178 (39.3) 86 (36.0) 46 (32.8) 0.33
Statin 285 (63.0) 139 (58.9) 79 (56.4) 0.29
OHA 325 (71.9) 0 (0.0) 0 (0.0) <0.001
Insulin 64 (14.1) 0 (0.0) 0 (0.0) <0.001
Values are expressed as medians (interquartile range) or number and percentage. *P <0.05 vs. PH; †P <0.05 vs. NGT; and ‡P <0.05 vs. DM.
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body-mass index; BMS, bare-metal stent; CABG, coronary artery bypass
graft; CI, cerebral infarction; DES, drug-eluting stent; DM, diabetes mellitus; eGFR, Estimated glomerular filtrating ratio; LVEF, left ventricular ejection fraction; MI,
myocardial infarction; NGT, normal glucose tolerance; OHA, oral hypoglycemia agent; PCI, percutaneous coronary intervention; PH, post-challenge hyperglycemia.
Table 2 Glucometabolic state and lipid profile of the 3 groups
DM (n=452) PH (n=236) NGT (n=140) P value
Glucometabolic state
FPG, mg/dl 140.0 (111.2-194.0)*† 94.0 (88.0-101.7)† 86.0 (82.2-91.0) <0.001
2-h PG, mg/dl - 189.5 (161.0-224.2)† 116.0 (97.0-128.0) <0.001
HbA1c, % 7.3 (6.8-8.3)*† 6.0 (5.8-6.3)† 5.8 (5.6-6.0) <0.001
Lipid profile, mg/dl
Total choresterol 181 (156–207.7) 176 (155.2-196.7) 177.5 (158.2-203.7) 0.37
Triglyceride 131.5 (94–194) 132 (101.2-178.7) 117 (91.5-162) 0.12
HDL-C 47 (40–55) 44 (37–51)†‡ 47.5 (39–57) 0.001
LDL-C 104 (85–126.7) 106.5 (88.2-126) 105.5 (88–125.7) 0.64
Values are expressed as medians (interquartile range). *P <0.05 vs. PH; †P <0.05 vs. NGT; and ‡P <0.05 vs. DM.
FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PG, plasma glucose.
Other abbreviations as in Table 1.
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NGT group (P <0.05, respectively). The glucometabolic
states and lipid profile of the three groups are shown in
Table 2. FPG and HbA1c levels were significantly higher
in the DM group than those of the PH and NGT group
(P <0.001, respectively). Compared with the NGT group,
FPG, 2-h PG, and HbA1c levels were significantly
higher in the PH group (p <0.001, respectively). In the
lipid profile, HDL-cholesterol level was significantly
lower in the PH groups compared with the DM and
NGT groups (P <0.05, respectively).Figure 2 Kaplan-Meier plot of the cumulative incidence of the
study endpoint between the three groups. The study endpoint
was defined as cardiovascular death, myocardial infarction, stroke,
and clinically-driven revascularization. Known DM = diabetes mellitus
(green line); NGT = normal glucose tolerance (blue line); PH = post-
challenge hyperglycemia (red line).Post-challenge hyperglycemia, known DM, and MACE
Clinical events in the three groups are summarized in
Table 3. As shown in Figure 2, the cumulative incidence of
MACE was significantly higher in the DM and PH groups
than in the NGT group (39.3% vs. 20.7%, P <0.001; 31.4%
vs. 20.7%, P=0.044, respectively), and there was trend
toward the higher MACE rate in the DM group compared
to the PH group (39.3% vs. 30.9%, P=0.056). Compared
with the NGT group, the cumulative incidence of revascu-
larization was significantly higher in the DM group (35.1%
vs. 18.5%, P <0.001) and tended to be higher in the PH
group (27.1% vs. 18.5%, P=0.067).
In the Cox regression analysis, known DM (Hazard
ratio [HR]: 2.16, 95% confidence interval (CI): 1.49-3.27,
P < 0.001), PH (HR: 1.62, 95% CI: 1.07-2.53, P = 0.023),
LDL-C >100 mg/dl (HR: 1.62, 95% CI: 1.26 to 2.10,
P < 0.001), and previous stroke (HR: 1.47, 95% CI: 1.03-
2.04, P = 0.034) were predictors of MACE in patients with
stable angina undergoing PCI (Table 4).Table 3 Cumulative incidence of clinical events during
the follow-up period
DM (n=452) PH (n=236) NGT (n=140) P value
MACE 178 (39.3)*† 74 (31.4)† 29 (20.7) <0.001
All-cause Death 37 (8.1)*† 8 (3.3) 3 (2.1) 0.006
Non-cardiovascular 21 (4.6) 4 (1.6) 3 (2.1) 0.08
Cardiovascular 16 (3.5) 4 (1.6) 0 (0.0) 0.041
Stroke 20 (4.4) 8 (3.3) 3 (2.1) 0.5
MI 12 (2.6) 6 (2.5) 2 (1.4) 0.7
Revascularization 159 (35.1)*† 64 (27.1) 26 (18.5) <0.001
PCI 157 (34.7)*† 63 (26.6) 26 (18.5) <0.001
TLR 47 (10.3)† 13 (5.5) 4 (2.8) 0.005
TVR 80 (17.6)*† 27 (11.4) 10 (7.1) 0.002
Non-TVR 101 (22.3) 42 (17.8) 19 (13.5) 0.055
CABG 12 (2.6) 3 (1.2) 0 (0.0) 0.09
Values are expressed as number and percentage. *P <0.05 vs. PH; †P <0.05 vs.
NGT. TLR, target lesion revascularization; TVR, target vessel revascularization.
Other abbreviations as in Table 1.Impaired glucose tolerance, newly detected DM, and
MACE
Figure 3 shows the results of a secondary analysis ad-
dressing the cumulative incidence of MACE in the cat-
egories of newly detected DM, IGT, NGT, and known
DM. Compared with the NGT group, there was trend
toward the higher MACE rate in the newly detected DM
group compared to the NGT group (34.0% vs. 20.7%,
P=0.075), whereas no significant difference in MACE
rate was found between patients with IGT and NGT
(P=0.27). There was no significant difference in the rate
of revascularization between the newly detected DM,
IGT, and NGT groups (Additional file 1: Table S1).
After adjustment for known DM, newly detected DM,
IGT, NGT, LDL-C >100 mg/dl, and previous stroke in
Cox regression analysis, adjusted HR were 1.75 (95% CI:
1.07-2.89, P=0.027), 1.53 (95% CI: 0.95-2.48, P=0.08),
and 2.16 (95% CI: 1.49-3.27, P <0.001) for patients with
newly detected DM, IGT, and known DM, respectively,
when compared with the NGT subjects.Table 4 Predictors of major adverse cardiovascular events
Adjusted HR 95% CI P value
Glucometabolic state
Normal glucose tolerance 1.00
Post-challenge hyperglycemia 1.59 1.04-2.48 0.029
Known DM 2.12 1.46-3.21 <0.001
LDL-cholesterol >100 mg/dl 1.62 1.26-2.10 <0.001
Previous stroke 1.46 1.03-2.02 0.034
CI=confidence interval; HR=hazard ratio. Other abbreviations as in Table 1.
Figure 3 Kaplan-Meier plot of the cumulative incidence of the
study endpoint between the 4 groups. Known DM = diabetes
mellitus (red line); Newly diagnosed DM = diabetes mellitus (green
line); IGT = impaired glucose tolerance (brown line); NGT = normal
glucose tolerance (blue line).
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The main findings of the present study are: (1) our study
was the analysis of a homogeneous group of patients
with stable angina undergoing PCI; (2) PH was associ-
ated with future cardiovascular events in patients with
stable angina undergoing PCI, which is mainly due to
the need for repeated revascularization; (3) The preva-
lence of glucometabolic abnormalities in our study was
very high (72.4%). Of these, 34.3% were classified as PH,
which was diagnosed using OGTT; (4) Known DM, PH,
LDL-C >100 mg/dl, and previous stroke were independ-
ent predictors of MACE in patients with stable angina
undergoing PCI.
Several studies have reported the impact of different
glucose abnormalities on clinical outcomes in patients
with cardiovascular disease [16,19-25]. However, most of
the studies were performed on heterogeneous groups of
patients, i.e., those with stable and unstable angina, myo-
cardial infarction, or heart failure. Furthermore, these
patients were also treated with multiple modalities, and
only in a few studies were all subjects treated with PCI.
Therefore, the main advantage of the present study was
the analysis of a homogeneous group of patients with
stable angina undergoing PCI.
The present study showed that PH was associated with
future cardiovascular events in patients with stable an-
gina undergoing PCI, which is mainly due to the need
for repeated revascularization. Previous studies have
shown that PH and hyperinsulinemia disrupt normal
endothelial function and accelerate the formation of ath-
erosclerotic plaques, leading to plaque rupture and subse-
quent thrombus formation [26-29]. Furthermore, PH and
hyperinsulinemia have been shown to be predictive of re-
stenosis after BMS implantation in nondiabetic patients
[30-32]. These findings are consistent with our currentobservations. The data available to date, however, are in-
sufficient to support the lowering of PH as a primary tar-
get to reduce the risk of macrovascular events in patients
with stable angina. Recently, the DIANA (Diabetes and
diffuse coronary Narrowing) study reported that improve-
ment in glycemic status at 1 year was associated with less
atheroma progression in Japanese early-stage DM patients
with CAD, regardless of the treatment, including life-style
intervention, voglibose or nateglinide treatment [33]. Al-
though this study could not assess the impact of improv-
ing glycemic status on MACE, it suggests the need for
intensive management of glycemic abnormalities in early-
stage DM. Furthermore, the benefits of early intensive
therapy to control blood glucose levels in patients with
newly diagnosed DM were sustained for up to 10 years
after cessation of intensive therapy [34]. Therefore, PH
might be considered a treatment target in patients with
stable angina undergoing PCI.
The prevalence of glucometabolic abnormalities in
our study was very high (72.4%). Of these, 34.3% were
classified as PH, which was diagnosed using OGTT.
This is concordant with the results from previous stud-
ies [9,12-14,16,35]. While OGTT is an indispensable tool
to detect glucometabolic abnormalities [36,37], FPG is still
often used for the diagnosis in daily practice. However, as
shown in DECODA (Diabetes Epidemiology: Collaborative
Analysis of Diagnostic Criteria in Asia) study [9], it would
be inappropriate to use the FPG criteria alone for screening
diabetes in Asian populations. Furthermore, current guide-
lines recommend that 75-g OGTT should be considered in
high-risk patients, i.e., those with cardiovascular disease
and an Hb1Ac level of 5.7 to 6.4% [38,39]. Therefore,
these facts suggest that it mandatory to perform OGTT in
patients with stable angina undergoing PCI, unless a
glucometabolic abnormality has been already established.
It has been reported that established DM deteriorates
the prognosis of patients with stable angina. However,
the impact of prediabetes (IGT and impaired fasting glu-
cose) on the clinical outcomes in patients with CAD re-
mains controversial. In our study, newly detected DM
affected clinical outcome, whereas IGT did not. In con-
trast, Sourij et al. [16] reported that vascular risk was
already significantly increased in angiographied coronary
patients with PH in the IGT range. Although this report
demonstrated an issue similar to our study, there were a
few differences between the two studies. Most import-
antly, significant stenoses were found in 57.4-68.0% of
subjects in this study, whereas all subjects underwent
PCI and 26% had multivessel coronary disease. While it
remains unclear how the patients were treated in this
study, the difference of the study population between
the two studies might affect the results. To elucidate the
impact of prediabetes on clinical outcome in CAD pa-
tients, further larger investigations will be needed.
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strated reductions in cardiovascular events and atheroma
progression [40-42]. Interestingly, Daida et al. reported
that plaque regression was less pronounced in patients
with high HbA1c levels compared with those with low
levels [43]. Thus, tight glucose control during statin ther-
apy may enhance plaque regression in patients with stable
angina. Furthermore, Bayturan et al. [44] reported that the
presence of DM and increased systolic blood pressure
were independently associated with plaque progression in
patients with LDL-C ≤70 mg/dl. These findings support
the concept that coronary atherosclerosis is a multifactor-
ial process that is likely to respond to global risk modifica-
tion. In the present study, LDL-C >100 mg/dl was an
independent predictor of MACE in patients with stable
angina undergoing PCI, whereas statins were used in ap-
proximately 60% of the subjects. Furthermore, ACE-I and
ARB were also used in only 60% of the subjects. This may
be due to our inadequate awareness regarding lipid lower-
ing therapy and antihypertensive agent for patients with
stable angina in the present study. Therefore, we should
reaffirm the importance of multifactorial intervention for
coronary risk factors to prevent future cardiovascular
events in patient with stable angina and glucometabolic
abnormalities.
Study limitations
There were several limitations in the present study. First,
the present study was a retrospective cohort study at a
single center. In addition, a quarter of eligible patients
did not have OGTT. Although the baseline characteris-
tics between patients with and without OGTT were
similar (Additional file 1: Table S2), selection bias may
exist and may have affected the conclusion. Second, 75-g
OGTT was performed 2 days after PCI. Ideally, it should
have been done prior to the PCI, but this was impossible
due to logistic reasons. However, a meta-analysis has
shown that it is reasonable to screen patients hospital-
ized for ACS for previously undiagnosed DM using an
OGTT [45]. Moreover, all subjects in the present study
had stable angina. Therefore, the result of OGTT in the
present study was thought to be acceptable. Third, we
excluded the patients with >80 years old and serum cre-
atinine >2.0 mg/dl in the present study because we had
performed OCTT based on a previous study [19]. There-
fore, further study will be needed to assess the impact of
PH on future cardiovascular events in clinical practice.
Fourth, we could not assess the impact of impaired
fasting glucose (IFG; FPG 110–125 mg/dl and 2-h PG
<140 mg/dl) on clinical outcomes in the present study
because patients with IFG were observed in only 2 pa-
tients. Fifth, we could not follow the changes in thera-
peutic agents during the follow-up. Therefore, these
findings may have biased the conclusion. Finally, wecould not identify whether early intervention for PH re-
sults in good clinical outcomes in the present study. Fur-
ther study is needed to identify the optimal therapies for
patients with stable angina and PH.
Conclusions
PH is associated with future cardiovascular events in pa-
tients with stable angina undergoing PCI. Our results
suggest that PH might be considered as a target of treat-
ment to prevent future cardiovascular events in patients
with stable angina undergoing PCI.
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